Circulating cell free tumor DNA as a biomarker in patients with neuroendocrine neoplasms

#3487

Introduction: There is a need to develop better biomarkers to monitor patients with neuroendocrine neoplasms (NENs).

Aim(s): Our aim was to identify and track plasma circulating cell free tumor DNA (ctDNA) in a cohort of patients using a personalised, patient specific approach.

Materials and methods: 35 serial plasma samples were collected from 9 patients with metastatic NENs (6 small intestinal (SI), 1 lung, 1 ovarian, and 1 pelvic; range 2-5 plasma samples per patient) over 2-25 months. Individual NEN specific somatic mutations were identified through whole exome sequencing of paired tumor-leucocyte DNA and were used to design a bespoke multi-variant Ampliseq™ HD ctDNA panel (5-20 variants per patient) for targeted next generation sequencing. Imaging and treatment were provided as per usual care.

Conference:

Presenting Author:

Authors: Gohil S, Hastings R, Page K, Iwuji C, Richards C,

Keywords: neuroendocrine, circulating cell free tumor derived DNA, ctDNA, biomarker, next generation sequencing, cell free DNA, PRRT,